Extraordinary General meeting of the company

Nicox (Euronext Paris : FR0013018124, COX, eligible PEA-PME), international society of Research and Development in ophthalmology, informs its shareholders that the Ordinary General Meeting held on may 16, 2017, and that all resolutions were approved. Furthermore, the Extraordinary General Meeting convened on first call could not deliberate for lack of quorum required.

Download the free guide
Boost your gains

The shareholders of the Company are accordingly invited to attend the Extraordinary General Meeting on second convocation on Tuesday, may 30, 2017 to 14 hours, in the offices of Drakkar D – BuroClub – room Columbus – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis, in order to deliberate on the same agenda and the same draft resolutions.

The information referred to in article R. 225-73-1 of the French Commercial Code, in particular the documents intended to be submitted to this general meeting, are published on the website of the Company www.nicox.com. They are also available and can be consulted at the registered office of the Company.

Shareholders may vote by proxy by the internet or attend the general meeting in person. A guide explaining how to vote, including how to vote by internet, is available on the website of Nicox. Shareholders may also contact the Investor Relations team by e-mail to the address Age2017@nicox.com for any questions on the voting procedures.

About Nicox
Nicox is an international company in Research & Development specializing in ophthalmology using scientific technologies innovative to keep the vision and improve eye health. Drawing on its expertise is exclusive in terms of release of nitric oxide, and other technologies, the Company develops a broad portfolio of new therapeutic products targeting multiple ocular pathologies, including glaucoma. The company currently has two products at the stage prior to approval by the Food and Drug Administration (FDA) and a portfolio of promising products, including nitric oxide-donating pure new generation, with the potential to treat various indications. Nicox is headquartered in Sophia Antipolis (France), is listed on Euronext Paris (Compartment B : Mid Caps ; Mnémo : COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150.

For more information on the Company : www.nicox.com

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply